Keytruda approved for melanoma

Share this content:

The Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs. Keytruda is the first approved drug that blocks a cellular pathway known as PD-1, which restricts the body's immune system from attacking melanoma cells.

close

Next Article in Products